LUCAR-G39D

N/A

Report date: 2024/05/31 20:00:45

Base Information

Drug NameLUCAR-G39D
Drug Alias NameLUCAR-G39D cells therapy(Legend Biotechnology)Targeting CD19/CD20 Dual-targeted Cell therapy(Legend Biotechnology)Dual-targeted Cell Preparation Targeting CD19/CD20 Cell therapy(Legend Biotechnology)LUCAR-G39D
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-CD19Anti-CD20T lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Legend Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A